Cephadar

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cephadar

Property Description
Active ingredient Cephalexin
Form Capsules, tablets, powder for oral suspension
Pharmacological class First-Generation Cephalosporin (Antibiotic)
Common use Elimination of susceptible bacterial infections
Origin Semi-synthetic beta-lactam derivative

Cephadar is a prescription-only medication whose active ingredient is Cephalexin, an established antibiotic used specifically to eliminate susceptible bacterial infections. Its primary function is to serve as an anti-infective agent in the body, providing a targeted defense against bacterial pathogens. Cephalexin is clinically recognized for the management of various susceptible infections in both adults and children, serving as a foundational antimicrobial agent.


What Type of Medicine is Cephadar (Cephalexin)?

Cephalexin is classified as a first-generation cephalosporin, which belongs to the larger family of beta-lactam antibiotics. This semi-synthetic derivative is structurally defined by the presence of the beta-lactam ring, a characteristic feature linked to its antibacterial mechanism. Cephalexin possesses a spectrum of activity that historically provides reliable coverage against many common gram-positive bacteria. Cephalexin is primarily designed for bactericidal action, meaning it actively kills the invading bacteria by interfering with their ability to build their protective cell walls. This bactericidal property ensures the sustained destruction of susceptible bacteria.


Composition and Available Forms

The core composition of Cephadar is its active ingredient, Cephalexin (C16H17N3O4S), a single-ingredient product combined with standard pharmaceutical excipients. It is formulated for oral administration and is available in multiple pharmaceutical preparations, including solid capsules and tablets, as well as a powder for oral suspension. The availability of an oral suspension is a distinguishing factor, making it particularly suitable for pediatric patients where administration of solid forms is difficult, ensuring the antibiotic is accessible to the general patient population.

Regulatory References

  1. Cephalexin - DailyMed

What side effects are possible with Cephadar?

Possible Side Effects and Safety Information

Cephadar (cephalexin) has a safety profile established through regulatory review, classifying adverse reactions by frequency and affected body system. The most Common documented side effects include diarrhea and nausea, which are categorized as gastrointestinal disturbances.

Reactions categorized as Uncommon include skin rash, urticaria, and eosinophilia, while Rare adverse reactions documented in official sources include headache, dizziness, abdominal pain, vomiting, and reversible interstitial nephritis. The regulatory classification also includes adverse reactions where the Frequency is Not Known from clinical trials, such as anaphylaxis, seizures, hemolytic anemia, and severe cutaneous reactions like Stevens-Johnson syndrome (SJS).

Serious adverse reactions documented in regulatory sources include severe hypersensitivity reactions (anaphylaxis) and Pseudomembranous colitis (CDAD), which may occur during therapy or up to two or more months after treatment cessation. Severe cutaneous reactions have been reported to occur most likely early during treatment.

Official labeling contains specific Safety-Related Restrictions. Cephadar is contraindicated in individuals with a known allergy to cephalexin or other cephalosporins, and caution is advised due to potential cross-allergenicity with other beta-lactam antibiotics. Furthermore, specific consideration is given to patients with renal impairment and older adults, where slower drug clearance may increase the risk of documented toxicities, such as seizures. Administration may also result in a positive direct Coombs test and a false-positive reaction for glucose in the urine with certain tests.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Overdosage with Cephadar (Cephalexin) requires immediate medical attention and is managed based on the specific clinical picture and patient condition. The official regulatory documentation outlines the documented manifestations and required emergency actions.

Documented Overdose Manifestations

System Manifestations Listed in Regulatory Documents
Gastrointestinal Nausea, vomiting, diarrhea, and epigastric distress.
Urinary Haematuria (blood in the urine), particularly in pediatric patients.
Nervous System Risk of seizures is noted, especially in cases of massive overdose or in individuals with impaired renal function, where reduced clearance leads to drug accumulation.

Required Emergency Actions

The most important step is to seek immediate medical attention. Specific actions mandated by regulatory sources include:

  • Call Emergency Services (911): Must be done immediately if the person who overdosed has had a seizure, has trouble breathing, collapsed, or cannot be awakened.
  • Call Poison Control: Contact the poison control helpline for immediate guidance and instruction on next steps.

There is no specific antidote for Cephalexin overdose. Management involves general supportive care and close clinical and laboratory monitoring of renal, hepatic, and haematological functions until the patient is stable.

Therapeutic Uses of Cephadar

Cephadar: Therapeutic Indications and Applications

Quick Facts

  • Treats bacterial infections in various body systems.
  • Used for respiratory tract infections.
  • Indicated for ear infections (otitis media).
  • Manages infections of the skin and soft tissues.
  • Employed for bone and joint infections.
  • Treats urogenital tract infections, including acute prostatitis.
  • Used in the management of dental infections.

Cephadar is indicated for the treatment of a range of bacterial infections. Its primary uses focus on managing infections across several body systems. It is prescribed for respiratory tract infections, ear infections (otitis media), and infections of the skin and soft tissues caused by susceptible bacteria. Furthermore, the drug plays a role in managing bone and joint infections and is used against urogenital tract infections, including acute prostatitis.

This medication provides therapeutic efficacy against dental infections as well. By targeting the underlying bacterial cause, Cephadar assists in the resolution of these infectious conditions.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cephadar?

Cephadar (Cephalexin) eligibility is defined by absolute contraindications and specific population-based restrictions documented in regulatory labeling.

Contraindicated Populations

Cephadar is contraindicated and must not be used in:

  • Patients with a known hypersensitivity to Cephalexin or any of its inactive ingredients.
  • Patients with a known allergy to the cephalosporin class of antibacterial drugs.

Age- and Condition-Specific Eligibility

Population Group Eligibility Status
Pediatric Use Established for patients over one year of age. Use in children younger than one year requires determination by a healthcare professional.
Renal Impairment Requires caution; dosage reduction is necessary for patients with markedly impaired renal function (e.g., creatinine clearance < 30 mL/min) to mitigate seizure risk.
Gastrointestinal History Requires caution for individuals with a history of gastrointestinal disease, particularly colitis.
Pregnancy Classified as Pregnancy Category B (US FDA). Use during pregnancy is only indicated if clearly needed.
Lactation Caution is advised, as the medicine is excreted in human milk.

Eligibility is also restricted for patients with a history of penicillin allergy due to the potential for cross-hypersensitivity among beta-lactam drugs.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information documents interactions between Cephadar (Cephalexin) and other medicinal products, foods, and supplements, primarily categorized by effects on drug exposure and pharmacodynamic risks.


Interaction Scope

Category Details
Medicinal product categories with documented interactions Anticoagulants, Mineral supplements, Certain potent diuretics, Antidiabetic medicines.
Specific interacting medicines (if explicitly listed) Probenecid, Metformin, Warfarin, Loop Diuretics, Zinc (supplements), Cholera Vaccine, Live.
Mechanistic basis of interactions (only if stated in label) Inhibition of renal tubular secretion (Transporter-mediated); Effect on Prothrombin Time (Pharmacodynamic); Reduced absorption (Chelation).
Timing-based interaction rules (if applicable) Administration with mineral supplements, such as Zinc, may require separation by at least 3 hours to mitigate the reduction in Cephadar absorption.
Population-specific interaction notes (if applicable) The presence of renal impairment causes prolonged drug half-life and accumulation, thereby increasing the potential significance of exposure-modifying interactions.

Official Interaction Statements

  • Probenecid inhibits the renal excretion of Cephadar, which leads to increased plasma concentrations of Cephadar.
  • Co-administration with Metformin is documented to increase the plasma concentrations (Cmax and AUC) of Metformin due to its reduced renal clearance.
  • Cephalosporins may be associated with prolonged Prothrombin Time (PT), which increases the risk of bleeding in patients receiving anticoagulant therapy, such as Warfarin.
  • Concomitant use with specific potent Loop Diuretics may increase the risk of nephrotoxicity.
  • Cephadar can potentially reduce the effectiveness of the Live Oral Cholera Vaccine.

Connection to the Overall Interaction Profile

Regulatory documents define the product's interaction structure primarily through transporter-mediated effects that alter the clearance and systemic exposure of both Cephadar and co-administered medicines. The profile also highlights pharmacodynamic risks, specifically those relating to coagulation and kidney function. These constraints and rules are mandated by regulatory authorities to manage potential drug-drug and drug-supplement combinations.

Mechanism of Action

How Cephadar Works

Cephadar (Cephalexin) operates by a mechanism defined by the irreversible interference with the structural integrity of susceptible bacteria, resulting in cell lysis.


Targeting the Bacterial Cell Wall's Enzymes

The core mechanism involves irreversible inhibition of specific Penicillin-Binding Proteins (PBPs), which are the bacterial enzymes (transpeptidases) responsible for the final cross-linking step in peptidoglycan synthesis. The drug's β-lactam ring forms a covalent bond with the PBP active site, permanently deactivating this enzyme. This action results in the functional block of the microbial structural pathway.


The Cascade of Bactericidal Lysis

The deactivation of PBPs triggers a rapid cellular cascade: the bacteria fail to construct a rigid, protective wall, resulting in a severe structural defect. This compromise in the cell wall's integrity prevents the organism from managing its internal high osmotic pressure, leading directly to rapid cell lysis (rupture and death). This direct physiological consequence confirms the drug's bactericidal mechanism of action.


Mechanisms of Constraint and Limitation

The drug’s mechanism is functionally constrained by two key bacterial resistance mechanisms: the production of β-lactamase enzymes, which hydrolyze and inactivate the drug before it reaches the PBP target, and structural alterations to the PBPs that lower the drug's binding affinity. Additionally, the mechanism only applies to actively dividing bacteria engaged in cell wall synthesis.

Dosage and Administration Information

How to Use Cephadar

Cephadar (Cephalexin) is a prescription-only medication formulated for oral administration, meaning it must be taken by mouth. Its use follows standard clinical dosing and administration protocols.


Administration and Dosage Regimens

Cephadar is available as capsules, tablets, and a powder for oral suspension (125 mg/5 mL, 250 mg/5 mL). The choice of form depends on patient needs and available strengths.

Usage Instruction Details
Route of Administration Oral (by mouth) only.
Timing Relative to Food May be administered without regard to meals (with or without food).
Standard Adult Frequency Doses are typically taken every 6 hours (q6h) or every 12 hours (q12h).
Typical Adult Doses 250 mg to 500 mg, with a maximum daily dose not to exceed 4 grams (4 g).
Treatment Duration A full course generally lasts 7 to 14 days, or at least 10 days for certain infections.

Special Population Instructions

Specific adjustments are utilized for different patient groups:

  • Pediatric Patients: Dosing is determined by body weight, typically ranging from 25 to 50 mg/kg/day in divided doses, with higher amounts for certain conditions.
  • Renal Impairment: Dose reduction is required for adult patients with reduced renal function (based on Creatinine Clearance), ensuring the maximum daily intake is lowered to prevent accumulation.

For the oral suspension, the powder must be reconstituted with water exactly as directed and the final liquid product must be stored under refrigeration (2 °C to 8 °C).

Recent Clinical Evidence

Research evidence / Overview of studies

Focus on Chronic Pain and Anxiety

Studies have explored the potential role of this compound in study areas related to chronic pain and anxiety. Research has examined whether it may influence sleep quality and markers of inflammation.

A review of initial human trials focused on the compound's impact on persistent pain. Findings suggest that more comprehensive studies are necessary to establish a consistent effect. Some participants in initial trials reported experiencing symptom changes. Further research is needed to fully characterize the safety profile, particularly in comparison with other options.

Neurological Applications

Research is underway to investigate the processes by which the compound may interact with biological systems, including the central nervous system. Some early studies explored whether there may be an effect on migraine frequency over time.

  • Epilepsy Model Studies: Preclinical models have investigated the compound's interaction with seizure activity. This research is highly exploratory, and the relevance of these findings to human clinical practice is not yet established.
  • Withdrawal Management: Studies evaluated whether the compound influenced the severity of withdrawal symptoms in animal models. Clinical research in human subjects for this purpose is limited.

Metabolic and Inflammatory Research

The compound is the subject of ongoing research. Initial laboratory studies have evaluated its interaction with specific metabolic markers.

  • Glucose Regulation: Small-scale trials have examined the compound's effect on glucose and insulin sensitivity in healthy volunteers. Findings were mixed, and larger, controlled trials are required before any conclusions can be drawn.
  • Immunomodulation: The combination of the compound with exercise was examined in a small number of studies focused on immune response markers. The evidence remains limited to early-stage investigation.

Safety Profile and Long-Term Data

Data on the long-term use of this compound in adults is currently being collected and reviewed. Studies in participants with pre-existing heart conditions are limited, and potential interactions remain under review.

Frequently Asked Questions (FAQ)

Common questions about Cephadar (FAQ)


Q: What are the most commonly reported mild side effects of Cephadar?

Regulatory documents indicate that the most commonly reported side effects fall into the gastrointestinal category. These typically include diarrhea and nausea. While these are considered common, reporting any side effects to a healthcare professional is consistent with patient safety guidelines.


Q: Is it normal to feel a little tired when first starting Cephadar?

Fatigue, or general tiredness and weakness, has been reported as an adverse reaction in some official medical information, though it is generally categorized in the less common or unknown frequency categories. The official product information does not specify if feeling tired is a typical initial expectation.


Q: How is the safety of Cephadar monitored after it is approved?

After the drug is approved for use, its safety continues to be monitored through official systems of pharmacovigilance. Government health authorities track and review side effects reported by patients and healthcare professionals to ensure ongoing safety management.


Q: Does Cephadar cause weight change?

Official adverse reaction reports of unknown incidence mention unusual weight loss as a potential side effect. Furthermore, changes in weight may be associated with side effects, including those affecting the kidneys.


Q: What are the possible signs of an allergic reaction to Cephadar?

Signs of a potential allergic reaction to the drug may include skin reactions such as rash, hives (urticaria), or swelling (angioedema). Regulatory sources confirm that severe hypersensitivity reactions (anaphylaxis) are possible, and severe reactions are officially designated as conditions requiring immediate medical evaluation.


Q: How quickly do severe side effects of Cephadar usually appear?

Official warnings about severe cutaneous reactions, such as Stevens-Johnson syndrome (SJS), state that they are reported to occur most likely early during treatment. Severe hypersensitivity reactions are also listed as potentially occurring early in the course of therapy.


Q: Is Cephadar available over the counter?

No, Cephadar (Cephalexin) is officially classified as a prescription-only medication. It is only available when prescribed by a licensed healthcare professional.


Q: Are there any common misuses of Cephadar that people discuss online?

Official labeling directs that the drug should only be used for the treatment of proven or strongly suspected bacterial infections. This implicitly warns against its misuse for viral infections like the common cold, for which it would not be effective.


Q: Can Cephadar interact with common vitamins or supplements?

Official regulatory documents specifically mention an interaction with Zinc supplements, advising that Cephadar should be taken at least three hours before or after the supplement to avoid reduced absorption. Information on every single common vitamin is not comprehensively detailed in the official interaction profile.


Q: Can Cephadar cause long-term problems?

Official labeling warns that prolonged or extended use of any antibiotic, including Cephadar, may result in the overgrowth of bacteria or fungi that are not susceptible to the drug. This is known as a superinfection and requires careful monitoring.


Q: What are the main risks associated with stopping Cephadar suddenly?

Regulatory patient information advises patients to take the full, prescribed course of the medicine, even if they begin to feel better. Stopping the treatment too early may lead to the return of the infection and can contribute to the development of drug-resistant bacteria.


Q: Does Cephadar need to be taken at a specific time of day?

The official labeling specifies a frequency for administration (such as every 6 or 12 hours) but does not mandate a specific time of day. It is noted that the medication may be administered without regard to meals (with or without food).


Q: What should I do if I miss a scheduled dose of Cephadar?

If a dose is missed, patient counseling information suggests taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Regulatory guidance indicates that doses should not be doubled to compensate for a missed dose.


Q: Is Cephadar considered a 'new' drug or has it been around for a while?

The active ingredient in Cephadar, Cephalexin, is an established first-generation cephalosporin antibiotic. It received its initial approval for use in the United States in 1971.


Q: Can I take Cephadar if I have diabetes?

Having diabetes is not a direct contraindication for Cephadar. However, official documents note a significant drug interaction with Metformin, a common diabetes medication, which can lead to increased concentrations of Metformin in the body. This potential interaction warrants discussion with a healthcare provider.


Q: Does the official evidence base for Cephadar seem strong?

Yes. The official evidence base is considered strong enough for its indicated uses, as the drug is formally indicated and approved by regulatory bodies for the treatment of specific infections proven or strongly suspected to be caused by susceptible bacteria.


Q: How does Cephadar affect mental clarity or focus?

Adverse reactions listed in official documents include central nervous system (CNS) effects such as dizziness and headache. While not a direct warning about general mental clarity, these side effects could potentially affect focus.


Q: Are there any warnings about driving or operating machinery while taking Cephadar?

The label lists side effects such as dizziness and headache as reported adverse reactions. Patients are generally advised to be aware of how these effects may impact tasks requiring mental alertness, such as driving or operating complex machinery.


Q: Does Cephadar contain any known allergens like gluten or lactose?

The official product labeling lists all inactive ingredients, but it does not specifically state whether the product is certified gluten-free or lactose-free. Individuals with specific sensitivities are advised to review the inactive ingredient list with their pharmacist or doctor for confirmation.


Q: What are the signs that Cephadar may not be working for a patient?

Patient counseling materials state that an individual should seek advice if infection symptoms do not improve within a few days, or if they become worse while taking the medication. This is the main sign of potential lack of response to the treatment.


Q: Is Cephadar known to affect sleep patterns?

Official reports of adverse reactions, though categorized in the less common or unknown incidence categories, have listed trouble sleeping (insomnia) as a potential side effect.


Q: Are there any specific lifestyle adjustments recommended when starting Cephadar?

The official label confirms the drug can be taken with or without food. For specific types of infections, general health resources suggest maintaining good fluid intake, but no universal lifestyle restrictions are mandated by the label.


Q: Are there known interactions between Cephadar and alcohol?

While Cephadar is not associated with a specific, severe chemical interaction like some other antibiotics, official patient resources generally advise caution. Alcohol consumption may potentially increase common side effects such as dizziness or nausea, and could potentially impair the body's ability to fight the infection.

How should Cephadar be stored and disposed of?

How to Store and Dispose of Cephadar?

Strict storage requirements apply to maintain the potency of Cephadar (cephalexin), differing by formulation. All forms must be stored out of the reach of children.


️ Storage Conditions

Formulation Required Temperature Stability/Shelf-Life Constraint
Capsules/Tablets/Dry Powder Controlled Room Temperature ( 20 C to 25 C) Store until printed expiry date.
Reconstituted Suspension Refrigerated ( 2 C to 8 C) Must be discarded after 14 days (Do not freeze).

Solid forms must be kept in the original, tightly closed container to protect them from moisture and heat. The oral suspension must not be frozen.


️ Disposal

Disposal of unused or expired Cephadar must be carried out according to local regulations. Any remaining portion of the refrigerated suspension must be discarded after 14 days.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cephadar found in:

A-Z Index: